Skip to main content
. 2022 Dec 10;15:170. doi: 10.1186/s13045-022-01379-0

Fig. 3.

Fig. 3

Overall survival of matched ZUMA-3 and SCHOLAR-3 treated patients. KaplanMeier OS estimates of ZUMA-3 and SCA patients who were previously naïve to blinatumomab and inotuzumab (SCA-1; A), patients who were previously treated with blinatumomab or inotuzumab (SCA-2, B) and all matched patients (SCA-combined; C). CR = complete remission. CRi = complete remission with incomplete hematological recovery. NE = not estimable